| Abstract | OBJECTIVE: To analyze the clinical efficacy of anti-tumor necrosis factor (TNF)-alpha therapy in the SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. We describe 2 new cases with ilium osteitis as the main SAPHO syndrome feature and review reported cases treated with anti-TNF-alpha. METHODS: A literature search of SAPHO syndrome cases treated with TNF-alpha blocking therapy with special emphasis on osteoarticular and skin responses was performed. RESULTS: Eighteen cases were identified: 17 SAPHO syndrome and 1 chronic recurrent multifocal osteomyelitis, a juvenile variant of SAPHO syndrome. Sixteen were reported cases and 2 were nonreported cases seen in our arthritis unit. Sixteen patients received infliximab and 2 received etanercept, with an early, sustained clinical improvement in most cases. CONCLUSIONS: Anti-TNF-alpha therapies are effective treatment for patients with refractory SAPHO syndrome, not only for cutaneous lesions but also for persistent bone lesions such as osteitis. |
| Authors | Concepción Moll, M Victoria Hernández, Juan D Cañete, José A Gómez-Puerta, Alex Soriano, Antonio Collado, Raimon Sanmartí
(Affiliation: Arthritis Unit, Rheumatology Department, Hospital Clínic, University of Barcelona, Barcelona, Spain.)
|
| Journal | Seminars in arthritis and rheumatism
(Semin Arthritis Rheum)
Vol. 37
Issue 5
Pg. 299-306
(Apr 2008)
ISSN: 0049-0172 United States |
| PMID | 17976692
(Publication Type: Journal Article, Review)
|
| Chemical References |
- Anti-Inflammatory Agents
- Antibodies, Monoclonal
- Tumor Necrosis Factor-alpha
- infliximab
|
| Topics |
- Acquired Hyperostosis Syndrome
(complications, diagnosis, drug therapy)
- Anti-Inflammatory Agents
(therapeutic use)
- Antibodies, Monoclonal
(therapeutic use)
- Diagnosis, Differential
- Humans
- Ilium
- Osteitis
(diagnosis, drug therapy, etiology)
- Treatment Outcome
- Tumor Necrosis Factor-alpha
(antagonists & inhibitors)
|
